Javascript must be enabled to continue!
ResearchEquals Policy: Updating research outputs transparently
View through CrossRef
This document sets out how ResearchEquals versions research outputs and applies updates to DOIs in Crossref metadata (i.e., [Crossmark Policy](https://www.crossref.org/documentation/crossmark/participating-in-crossmark#00280)). In short, we provide one Digital Object Identifier (DOI) per version and have one DOI that always points to the latest version (akin to the versioning done by [Zenodo](https://zenodo.org/help/versioning)). Each version is marked using [Semantic Versioning](https://semver.org/) and optionally accompanied by a CHANGELOG (as provided by the author). This version history is included alongside each version of the output, to provide a clear contextual view of the research on display. All versions >1.0.0 result in the DOI metadata being marked with a new version.
Our policy on versioning outputs transparently solidifies our commitment to allow for knowledge to evolve in flexible manners. Further work is needed to create something akin to editorial oversight of the research shared on ResearchEquals that has the option to add expressions of concern, retractions, and other updates.
Title: ResearchEquals Policy: Updating research outputs transparently
Description:
This document sets out how ResearchEquals versions research outputs and applies updates to DOIs in Crossref metadata (i.
e.
, [Crossmark Policy](https://www.
crossref.
org/documentation/crossmark/participating-in-crossmark#00280)).
In short, we provide one Digital Object Identifier (DOI) per version and have one DOI that always points to the latest version (akin to the versioning done by [Zenodo](https://zenodo.
org/help/versioning)).
Each version is marked using [Semantic Versioning](https://semver.
org/) and optionally accompanied by a CHANGELOG (as provided by the author).
This version history is included alongside each version of the output, to provide a clear contextual view of the research on display.
All versions >1.
0 result in the DOI metadata being marked with a new version.
Our policy on versioning outputs transparently solidifies our commitment to allow for knowledge to evolve in flexible manners.
Further work is needed to create something akin to editorial oversight of the research shared on ResearchEquals that has the option to add expressions of concern, retractions, and other updates.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
Piece by piece: Collaborative mosaic-making for inclusive policy development
Piece by piece: Collaborative mosaic-making for inclusive policy development
This report sets out the findings from one of four projects commissioned by Wellcome Policy Lab to pilot creative approaches to policy development. In this project, Scientia Script...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Responsibilised Resilience? Reworking Neoliberal Social Policy Texts
Responsibilised Resilience? Reworking Neoliberal Social Policy Texts
Introduction This essay begins with the premise that resilience, broadly defined as positive adaptation despite adversity (Garmezy and Rutter), and resilience building are importa...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
ACKNOWLEDGMENTS
ACKNOWLEDGMENTS
The UP Manila Health Policy Development Hub recognizes the invaluable contribution of the participants in theseries of roundtable discussions listed below:
RTD: Beyond Hospit...
European Economic Integration
European Economic Integration
This book investigates the evolution of the integration process of the European Union (EU) under the lenses of economic development. The process of the European Economic Integratio...

